Molecular landscape of 
TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients. This evidence concerns the gene TP53 and breast carcinoma.